抗帕金森病药物的研究进展

发布时间：2018-06-06 15:41

本文选题：抗帕金森病药物 + 左旋多巴　；参考：《中国药房》2017年08期

【摘要】：目的:了解抗帕金森病(PD)药物的研究进展。方法:查阅近年来国内外相关文献,就抗PD的临床治疗药物、新型药物及候选药物的研究进展进行归纳和总结。结果与结论:左旋多巴(L-DOPA)类制剂为治疗PD最有效的药物,长期应用L-DOPA类制剂会出现严重的运动并发症。多巴胺受体激动药以选择性高、半衰期长、具有神经保护作用等优势,用于单独治疗早期PD或辅助L-DOPA治疗晚期PD,可推迟或缓解运动并发症的发生,是治疗PD的一线药物。抗PD新型药物的作用靶点主要为α-肾上腺素受体、5-羟色胺(5-HT)受体、腺苷A2A受体和谷氨酸受体。作用于5-HT受体的匹莫范色林在治疗PD精神异常方面有效且耐受性好;单胺氧化酶-B抑制剂沙芬酰胺,α-肾上腺素受体拮抗药菲帕麦唑,5-HT受体激动药候选药物SUNN4057、F15599,腺苷A2A受体拮抗药伊曲茶碱及侯选药物SYNN15,谷氨酸受体拮抗药候选药物ADS-5102、ADX48621等均可辅助L-DOPA显著改善晚期PD患者的运动症状,为PD治疗提供了新的选择。
[Abstract]:Objective: to investigate the research progress of anti Parkinson disease (PD) drugs. Methods: the research progress of clinical drugs, new drugs and candidate drugs for anti-PD were summarized and summarized by referring to the relevant literatures at home and abroad in recent years. Results & conclusion: L-DOPA is the most effective drug in the treatment of PD. The long-term application of L-DOPA can cause severe sports complications. Dopamine receptor activators have the advantages of high selectivity, long half-life, neuroprotective effect and so on. They can be used in the treatment of early PD or L-DOPA alone, can delay or alleviate the occurrence of motor complications, and are the first-line drugs in the treatment of PD. The main targets of anti-PD drugs are 伪 -adrenergic receptor 5-HT, adenosine A2A receptor and glutamate receptor. Pimovanserin, which acts on 5-HT receptor, is effective and well tolerated in the treatment of PD psychosis. Monoamine Oxidase B inhibitor Safenamide, 伪 -adrenergic receptor antagonist FUNN4057 F15599, adenosine A2A receptor antagonist A2A antagonist itroline and candidate drug SYN15, glutamate receptor antagonist ADS-5102ADX48621, etc. L-DOPA can significantly improve the motor symptoms of patients with advanced PD. It provides a new choice for PD therapy.
【作者单位】：河北科技大学化学与制药工程学院;
【分类号】：R742.5

【参考文献】